Effects of Different Drug Therapies and COVID-19 mRNA Vaccination on Semen Quality in a Man with Ankylosing Spondylitis: A Case Report
Authors:
- Katerina ChatzimeletiouKCKaterina Chatzimeletiou
- Alexandra FlevaAFAlexandra Fleva
- Antonia SiogaASAntonia Sioga
- Ioannis GeorgiouIoannis Georgiou
- Theodoros-Thomas NikolopoulosTNTheodoros-Thomas Nikolopoulos
- Maria MarkopoulouMMMaria Markopoulou
- Nikos PetrogiannisNPNikos Petrogiannis
- George AnifandisGeorge Anifandis
- Antonios PatrikiouAPAntonios Patrikiou
- Efstratios KolibianakisEKEfstratios Kolibianakis
- Anastasia GiannakouAGAnastasia Giannakou
- Grigoris GrimbizisGGGrigoris Grimbizis
Open Access
Abstract
Background and Objectives: Ankylosing spondylitis (AS) is a condition that affects 0.1% to 0.5% of the adult population. The aim of this case report was to investigate the possible effects of the drugs taken for treatment of AS as well as mRNA vaccination for COVID-19 on semen quality by performing a highly detailed analysis. Materials and Methods: Sperm characteristics were examined by light microscopy, DNA fragmentation (DFI) was analysed by flow cytometry and morphology was evaluated by transmission electron microscopy (TEM). Results: Semen analysis under therapy with (1) celecoxib and sulphasalazine showed: concentration 47 million/mL, 53% progressive motility, 7% normal morphology and 9.6% DFI, (2) Golimumab and before mRNA Vaccination showed: concentration 108 million/mL, 82% progressive motility, 1% normal morphology and 7.6% DFI, and (3) Golimumab and after 3 doses of mRNA Vaccination showed: concentration 142 million/mL, 85% progressive motility, 1% normal morphology and 6.8% DFI. TEM revealed head, neck and tail abnormalities, as well as the presence of cells with incomplete spermiogenesis white cells and phagocytes in the sample under therapy with celecoxib and sulphasalazine. Golimumab treatment lead to an increased incidence of elongated heads but in general reduced inflammation as no white cells were evident in TEM. Conclusion: The anti-inflamatory drugs celecoxib and sulphasalazine had no adverse effect on sperm quality as all parameters were within normal limits and the patient achieved under that treatment 2 pregnancies following natural conception that lead to the birth of a healthy boy and girl respectively. Anti-TNFa treatment with Golimumab exerted a negative effect on morphology but not on concentration, motility and DFI. After 3 doses of mRNA Vaccination, sperm concentration increased while motility, morphology and DFI remained similar to the values before vaccination suggesting no negative effect of the mRNA vaccine for COVID-19 on sperm quality.Keywords
This publication has 49 references indexed in Scilit:
- The anti‐inflammatory drug celecoxib inhibits t‐type Ca 2+ currents in spermatogenic cells yet it elicits the acrosome reaction in mature spermFEBS Letters, 2013
- Association of TNFα, TNFR1, and TNFR2 Polymorphisms With Sperm Concentration and MotilityJournal of Andrology, 2012
- Gonadal function in male patients with ankylosing spondylitisScandinavian Journal of Rheumatology, 2012
- Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritisAnnals of the Rheumatic Diseases, 2010
- World Health Organization reference values for human semen characteristics*‡Human Reproduction Update, 2009
- Effects of chronic celecoxib on testicular function in normal and lipopolysaccharide‐treated ratsInternational Journal of Andrology, 2009
- Standards for investigation of human semen Untersuchungsstandards für das menschliche Sperma La standardisation de l'analyse du sperme humainAndrologia, 2009
- Influence of Salazosulphapyridine and 5-Aminosalicylic Acid on Seminal Qualities and Male Sex HormonesScandinavian Journal of Gastroenterology, 1988
- Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution.Gut, 1987
- Sulphasalazine and SpermatogenesisDigestion, 1982